Compare RNAZ & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNAZ | DRCT |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 8.9M |
| IPO Year | 2021 | 2022 |
| Metric | RNAZ | DRCT |
|---|---|---|
| Price | $9.39 | $1.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $280.00 | ★ $330.00 |
| AVG Volume (30 Days) | 135.8K | ★ 7.3M |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,369,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.08 | $1.58 |
| 52 Week High | $399.00 | $80.30 |
| Indicator | RNAZ | DRCT |
|---|---|---|
| Relative Strength Index (RSI) | 47.22 | 50.16 |
| Support Level | $8.35 | $1.80 |
| Resistance Level | $10.00 | $6.04 |
| Average True Range (ATR) | 0.98 | 0.68 |
| MACD | -0.10 | -0.13 |
| Stochastic Oscillator | 13.17 | 3.36 |
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.